Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Bauml Discusses Immunotherapy in Head and Neck Cancer

Joshua Bauml, MD
Published: Tuesday, Jul 18, 2017



Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.

Bauml says that immunotherapy has a key role to play in the treatment of head and neck cancer. The arrival of PD-1 inhibitors, especially for patients with metastatic disease, has brought promise to the treatment landscape.

Specifically, Bauml says, head and neck cancer has overregulation of PD-L1 and PD-L2, as well as being virally mediated, making it an appropriate setting for immunotherapy.
 


Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.

Bauml says that immunotherapy has a key role to play in the treatment of head and neck cancer. The arrival of PD-1 inhibitors, especially for patients with metastatic disease, has brought promise to the treatment landscape.

Specifically, Bauml says, head and neck cancer has overregulation of PD-L1 and PD-L2, as well as being virally mediated, making it an appropriate setting for immunotherapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x